|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Bellicum Pharmaceuticals, Inc (BLCM) |
|
|
$0.07 0.00 (0.00%) as of 4:30 Mon 3/4
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
6,100,000 |
| Market
Cap: |
455.98(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0745 - $0.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Slawin Kevin M. |
Chief Technology Officer |
• • – |
2015-07-15 |
4 |
AS |
$20.00 |
$30,000 |
D/D |
(1,500) |
163,008 |
|
- |
|
| Spencer David M. |
Chief Scientific Officer |
• – – |
2015-07-02 |
4 |
OE |
$2.55 |
$51,000 |
D/D |
20,000 |
183,600 |
|
- |
|
| Moseley Annemarie |
COO/EVP Clinical Development |
• – – |
2015-07-01 |
4 |
AS |
$20.60 |
$721,622 |
D/D |
(35,000) |
122 |
|
- |
|
| Moseley Annemarie |
COO/EVP Clinical Development |
• – – |
2015-07-01 |
4 |
OE |
$2.55 |
$89,250 |
D/D |
35,000 |
35,122 |
|
- |
|
| Moseley Ken |
Sr. VP and General Counsel |
• – – |
2015-07-01 |
4 |
AS |
$20.60 |
$309,267 |
D/D |
(15,000) |
97 |
|
- |
|
| Moseley Ken |
Sr. VP and General Counsel |
• – – |
2015-07-01 |
4 |
OE |
$2.55 |
$38,250 |
D/D |
15,000 |
15,097 |
|
- |
|
| Spencer David M. |
Chief Scientific Officer |
• – – |
2015-06-16 |
4/A |
AS |
$22.82 |
$459,173 |
D/D |
(20,000) |
163,600 |
|
- |
|
| Spencer David M. |
Chief Scientific Officer |
• – – |
2015-06-16 |
4 |
AS |
$22.82 |
$459,173 |
D/D |
(20,000) |
162,754 |
|
- |
|
| Mcguyer Investments Ltd. |
10% Owner |
– – • |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
44,735 |
2,215,398 |
|
- |
|
| Mcguyer Investments Ltd. |
10% Owner |
– – • |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,023,605 |
2,170,663 |
|
- |
|
| Farrell Thomas J. |
President and CEO |
• • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
607 |
70,717 |
|
- |
|
| Farrell Thomas J. |
President and CEO |
• • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
17,169 |
70,110 |
|
- |
|
| Remeditex Ventures Llc |
10% Owner |
– – • |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
43,563 |
1,807,603 |
|
- |
|
| Remeditex Ventures Llc |
10% Owner |
– – • |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,764,040 |
1,764,040 |
|
- |
|
| Mcguyer Frank B. |
Director |
– • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
44,735 |
2,215,398 |
|
- |
|
| Mcguyer Frank B. |
Director |
– • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,023,605 |
2,170,663 |
|
- |
|
| Slawin Kevin M. |
CMO and CTO |
• • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
37,743 |
164,507 |
|
- |
|
| Slawin Kevin M. |
CMO and CTO |
• • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,537 |
115,198 |
|
- |
|
| Slawin Kevin M. |
CMO and CTO |
• • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
339,955 |
112,661 |
|
- |
|
| Spencer David M. |
Chief Scientific Officer |
• – – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
27,225 |
182,754 |
|
- |
|
| Brown James F |
Director |
– • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
23,300 |
905,322 |
|
- |
|
| Brown James F |
Director |
– • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
882,022 |
882,022 |
|
- |
|
| Musso Alan A |
CFO and Treasurer |
• – – |
2014-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
117,647 |
117,647 |
|
- |
|
| Mcguyer Investments Ltd. |
10% Owner |
– – • |
2014-12-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
147,058 |
|
- |
|
| Spencer David M. |
Chief Scientific OfficerOffice |
• – – |
2014-12-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
155,529 |
|
- |
|
179 Records found
|
|
Page 7 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
